High-intensity focused ultrasound ablation in the treatment of fumarate hydratase-deficient uterine leiomyoma.

IF 3 3区 医学 Q2 ONCOLOGY
International Journal of Hyperthermia Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI:10.1080/02656736.2024.2384459
Luyao Zhang, Zhouzhou Liao, Jianfa Jiang
{"title":"High-intensity focused ultrasound ablation in the treatment of fumarate hydratase-deficient uterine leiomyoma.","authors":"Luyao Zhang, Zhouzhou Liao, Jianfa Jiang","doi":"10.1080/02656736.2024.2384459","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the efficacy and safety of high-intensity focused ultrasound (HIFU) ablation for treating fumarate hydratase (FH)-deficient uterine leiomyomas.</p><p><strong>Method: </strong>Ten patients with FH-deficient uterine leiomyomas treated with HIFU ablation at the Third Xiangya Hospital from July 2017 to January 2023 were enrolled in this study. The effectiveness and adverse effects of HIFU were analyzed.</p><p><strong>Results: </strong>The median age of the patients who received HIFU was 32.0 years (range: 28-41 years). Only 2 patients had solitary uterine leiomyomas, whereas the remaining 8 patients had multiple uterine leiomyomas. The median diameter of the largest myoma was 56 mm (range: 41-99 mm). Magnetic resonance imaging showed that the FH-deficient uterine leiomyomas of 8 patients presented as mixed intensity on T2WI, that of one patient was hypointense, and that of another patient was hyperintense on T2WI. All patients successfully underwent HIFU ablation in one session without severe adverse effects. The median nonperfusion volume ratio (NPVR) was 40% (30.0%-78.0%) after HIFU treatment. Four patients had NPVR ≥70%. At 3-month follow-up after HIFU ablation, the clinical symptoms of 5 of the 8 patients with symptoms before treatment were relieved. Six months after treatment, 4 of the 8 patients with symptoms were still in remission. All patients received reintervention by March 2024. The reintervention rates were 20%, 70%, and 90% at 12, 24, and 36 months, respectively, after HIFU ablation.</p><p><strong>Conclusion: </strong>HIFU is a safe and feasible treatment for FH-deficient uterine leiomyomas, and most patients show effective results in the short term after treatment. However, the reintervention rates are high, and the long-term effects are limited.</p>","PeriodicalId":14137,"journal":{"name":"International Journal of Hyperthermia","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hyperthermia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02656736.2024.2384459","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to explore the efficacy and safety of high-intensity focused ultrasound (HIFU) ablation for treating fumarate hydratase (FH)-deficient uterine leiomyomas.

Method: Ten patients with FH-deficient uterine leiomyomas treated with HIFU ablation at the Third Xiangya Hospital from July 2017 to January 2023 were enrolled in this study. The effectiveness and adverse effects of HIFU were analyzed.

Results: The median age of the patients who received HIFU was 32.0 years (range: 28-41 years). Only 2 patients had solitary uterine leiomyomas, whereas the remaining 8 patients had multiple uterine leiomyomas. The median diameter of the largest myoma was 56 mm (range: 41-99 mm). Magnetic resonance imaging showed that the FH-deficient uterine leiomyomas of 8 patients presented as mixed intensity on T2WI, that of one patient was hypointense, and that of another patient was hyperintense on T2WI. All patients successfully underwent HIFU ablation in one session without severe adverse effects. The median nonperfusion volume ratio (NPVR) was 40% (30.0%-78.0%) after HIFU treatment. Four patients had NPVR ≥70%. At 3-month follow-up after HIFU ablation, the clinical symptoms of 5 of the 8 patients with symptoms before treatment were relieved. Six months after treatment, 4 of the 8 patients with symptoms were still in remission. All patients received reintervention by March 2024. The reintervention rates were 20%, 70%, and 90% at 12, 24, and 36 months, respectively, after HIFU ablation.

Conclusion: HIFU is a safe and feasible treatment for FH-deficient uterine leiomyomas, and most patients show effective results in the short term after treatment. However, the reintervention rates are high, and the long-term effects are limited.

高强度聚焦超声消融治疗富马酸氢化酶缺陷型子宫肌瘤。
研究目的本研究旨在探讨高强度聚焦超声(HIFU)消融术治疗富马酸氢化酶(FH)缺陷型子宫白肌瘤的有效性和安全性:本研究入选了2017年7月至2023年1月在湘雅三医院接受HIFU消融治疗的10例FH缺陷型子宫白肌瘤患者。对HIFU的疗效和不良反应进行分析:接受HIFU治疗的患者中位年龄为32.0岁(范围:28-41岁)。只有 2 例患者为单发子宫肌瘤,其余 8 例患者为多发性子宫肌瘤。最大肌瘤的中位直径为 56 毫米(范围:41-99 毫米)。磁共振成像显示,8 名患者的 FH 缺失型子宫肌瘤在 T2WI 上呈混合强度,一名患者的肌瘤呈低密度,另一名患者的肌瘤在 T2WI 上呈高密度。所有患者均在一次治疗中成功接受了 HIFU 消融术,未出现严重不良反应。HIFU 治疗后,非灌注容积比(NPVR)的中位数为 40%(30.0%-78.0%)。四名患者的 NPVR ≥70%。在 HIFU 消融术后 3 个月的随访中,8 位治疗前有症状的患者中有 5 位的临床症状得到缓解。治疗 6 个月后,8 名有症状的患者中仍有 4 人的症状得到缓解。所有患者均在 2024 年 3 月前接受了再次介入治疗。HIFU消融术后12个月、24个月和36个月的再介入率分别为20%、70%和90%:结论:HIFU 是治疗 FH 缺失型子宫肌瘤的一种安全可行的方法,大多数患者在治疗后短期内就能显示出有效的疗效。结论:HIFU 是治疗 FH 缺失型子宫肌瘤的一种安全、可行的方法,大多数患者在治疗后短期内都能获得有效的效果,但再次干预率较高,长期效果有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
12.90%
发文量
153
审稿时长
6-12 weeks
期刊介绍: The International Journal of Hyperthermia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信